Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library. In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.…
Myomo (MYO) Upgraded to Buy: What Does It Mean for the Stock?
Myomo (NYSEAMERICAN: MYO) is listed on NYSE American, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 194 employees.
The shares were at 0.8110 USD on 20 November 2026, down 5.0% over 52 weeks. Its 52-week range is 0.6050 USD to 1.885 USD: the price is 57.0% below the high and 34.0% above the low.
Its market capitalisation is 32.52M USD.
Myomo reports return on equity of -136.6%, an operating margin of -21.8% and revenue up 22.2% year over year.
Its debt exceeds its cash by 9.46M USD, a debt-to-equity ratio of 1.70. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 8 March 2027.